Associated Papers
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.
Chen L et al.
Nature Communications, 2018
Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail.
Ong M et al.
British Journal of Cancer, 2014
Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases.
Hohensee I et al.
The American Journal of Pathology, 2013
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
Janku F et al.
Cancer Research, 2013
PIK3CA mutations in advanced cancers: characteristics and outcomes.
Janku F et al.
Oncotarget, 2012
The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors.
Stehr H et al.
Molecular Cancer, 2011
21575214 (PubMed )
Supplement: 1476-4598-10-54-S3.XLS › mutations.txt
Select a paper to view details